IDEAYA Biosciences, Inc.
IDYA
$28.32
$0.110.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3,118.14% | 3,024.43% | 5,377.66% | -41.47% | -54.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,118.14% | 3,024.43% | 5,377.66% | -41.47% | -54.85% |
| Cost of Revenue | 5.20% | 6.80% | 90.57% | 101.67% | 123.43% |
| Gross Profit | 63.81% | 66.63% | 18.95% | -112.51% | -144.87% |
| SG&A Expenses | 55.17% | 61.11% | 56.50% | 45.44% | 47.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.27% | 13.19% | 85.29% | 92.39% | 110.31% |
| Operating Income | 49.09% | 51.28% | 7.06% | -100.76% | -126.39% |
| Income Before Tax | 54.39% | 58.58% | 9.76% | -115.82% | -138.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.39% | 58.58% | 9.76% | -115.82% | -138.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.39% | 58.58% | 9.76% | -115.82% | -138.25% |
| EBIT | 49.09% | 51.28% | 7.06% | -100.76% | -126.39% |
| EBITDA | 49.53% | 51.75% | 7.19% | -102.12% | -128.50% |
| EPS Basic | 55.96% | 61.00% | 20.97% | -73.55% | -79.26% |
| Normalized Basic EPS | 56.08% | 60.75% | 15.94% | -71.80% | -76.90% |
| EPS Diluted | 55.37% | 60.37% | 20.24% | -73.55% | -79.26% |
| Normalized Diluted EPS | 55.62% | 60.26% | 15.24% | -71.80% | -76.90% |
| Average Basic Shares Outstanding | 4.25% | 8.37% | 15.83% | 25.88% | 32.44% |
| Average Diluted Shares Outstanding | 4.59% | 8.73% | 16.21% | 25.88% | 32.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |